Now live: Pro — the full 13F research suite for serious investorsSee pricing →
MPM ASSET MANAGEMENT LLC

Q3 2025 · 13F-HR

MPM ASSET MANAGEMENT LLCholdings as filed

Filed 2025-11-14 · accession 0001193125-25-283116

$44.5M
Reported value
4
Positions
2025-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
29384C108TRDAEntrada Therapeutics, Inc.$25.4M57.1%4,381,062CommonSOLE
26818M108DYNDyne Therapeutics, Inc.$8.6M19.4%682,376CommonSOLE
95075A107HOWLWerewolf Therapeutics, Inc.$8.5M19.1%4,309,860CommonSOLE
760273102RPTXRepare Therapeutics, Inc.$2.0M4.43%1,121,318CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.